Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).

被引：1
|
作者：
Barata, Pedro C.
Emamekhoo, Hamid
Mendiratta, Prateek
Gopalakrishnan, Dharmesh
Koshkin, Vadim S.
Tyler, Allison Janine
Ornstein, Moshe Chaim
Grivas, Petros
Gilligan, Timothy D.
Rini, Brian I.
Kyriakopoulos, Christos
Garcia, Jorge A.
机构：
[1] Cleveland Clin, Cleveland, OH USA
[2] Univ Wisconsin, Madison, WI USA
[3] Cleveland Clin Taussig Canc Insitute, Cleveland, OH USA
[4] Univ Wisconsin Carbone Canc Ctr, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.305
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
305
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).
    Lombana Quinonez, Milton Alberto
    Milena Torres, Ana
    Gonzalez, Guido
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [33] ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
    Smith, Matthew Raymond
    Saad, Fred
    Hussain, Maha
    Sternberg, Cora N.
    Fizazi, Karim
    Yamada, Karin Sayuri
    Kappeler, Christian
    Kuss, Iris
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [34] Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
    Kwon, Whi-An
    Joung, Jae Young
    Lee, Jung Eun
    Choi, Se Young
    Kim, Sung Han
    Seo, Ho Kyung
    Lee, Kang Hyun
    Kim, Choung-Soo
    INVESTIGATIVE AND CLINICAL UROLOGY, 2019, 60 (03) : 195 - 201
  • [35] Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer
    Azad, Arun A.
    Tran, Ben
    Davis, Ian D.
    Parente, Phillip
    Evans, Melanie
    Wong, Shirley
    Brown, Stephen
    Evans, Sue
    Millar, Jeremy
    Murphy, Declan G.
    Papa, Nathan
    INTERNAL MEDICINE JOURNAL, 2022, 52 (08) : 1339 - 1346
  • [36] ERG expression can predict the outcome of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer
    Kuronya, Zsofia
    Sukosd, Farkas
    Varga, Linda
    Biro, Krisztina
    Gyergyay, Fruzsina
    Geczi, Lajos
    Nagyivanyi, Krisztian
    Jorgo, Kliton
    Szarvas, Tibor
    Kovacs, Agnes
    Laczo, Ibolya
    Varga, Zoltan
    Posfai, Boglarka
    Pepo, Judit
    Maraz, Aniko
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (04) : 289.e1 - 289.e9
  • [37] Androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: ARCHES
    von Bueren, Moritz
    Armstrong, Andrew J.
    Szmulewitz, Russell
    Petrylak, Daniel
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Stenzl, Arnulf
    SWISS MEDICAL WEEKLY, 2019, 149 : 16S - 16S
  • [38] Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy
    Liaw, Bobby C.
    Shevach, Jeffrey
    Oh, William K.
    CURRENT UROLOGY REPORTS, 2015, 16 (03)
  • [39] Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy
    Bobby C. Liaw
    Jeffrey Shevach
    William K. Oh
    Current Urology Reports, 2015, 16
  • [40] Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy thorn Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
    Francini, Edoardo
    Yip, Steven
    Ahmed, Shubidito
    Li, Haocheng
    Ardolino, Luke
    Evan, Carolyn P.
    Kaymakcalan, Marina
    Shaw, Grace K.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    Alimohamed, Nimira S.
    Joshua, Anthony M.
    Heng, Daniel Y. C.
    Sweeney, Christopher J.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 130 - 134
12345